| Trial ID: | L0617 |
| Source ID: | IRCT201410052394N13
|
| Associated Drug: |
Probiotic
|
| Title: |
Assessing the Effects of probiotic and prebiotic supplementation on serum hepatic enzymes, Insulin resistance, hs-CRP, Lipid profile, leptin and Adiponectin in patients with NAFLD
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non alcoholic fatty liver. <br>Other diseases of liver;Other diseases of liver
|
| Interventions: |
Intervention 1: Intervention group 1:<br>Patients in the group receiving the probiotic supplement, 1 capsule contains a combination of probiotics comprising of five bacterial species ( 5 billion active cell, containing Lactobacillus casei, Lactobacillus r
|
| Outcome Measures: |
ALT. Timepoint: At baseline, after 12 weeks. Method of measurement: photometric assay.;AST. Timepoint: At baseline, after 12 weeks. Method of measurement: photometric assay.;?GT. Timepoint: At baseline, after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;ALP. Timepoint: At baseline, after 12 weeks. Method of measurement: photometric assay.;Hs-CRP. Timepoint: At baseline, after 12 weeks. Method of measurement: ELISA.;Leptin. Timepoint: At baseline, after 12 weeks. Method of measurement: ELISA.;Adiponectin. Timepoint: At baseline, after 12 weeks. Method of measurement: ELISA.;Insulin. Timepoint: At baseline, after 12 weeks. Method of measurement: ELISA.;HOMA-IR. Timepoint: At baseline, after 12 weeks. Method of measurement: Serum insulin*FBS/405.;QUICKI. Timepoint: At baseline, after 12 weeks. Method of measurement: Calculation.;Fasting Glucose. Timepoint: At baseline, after 12 weeks. Method of measurement: GOD/POD.;TG. Timepoint: At baseline, after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;Cholestrol. Timepoint: At baseline, after 12 weeks. Method of measurement: Enzymatic colorimetric assay.;LDL. Timepoint: At baseline, after 12 weeks. Method of measurement: Calculation.;Blood pressure. Timepoint: At baseline, after 12 weeks. Method of measurement: sphygmomanometer.Body mass index. Timepoint: At baseline, after 12 weeks. Method of measurement: calculation.;WHR. Timepoint: At baseline, after 12 weeks. Method of measurement: calculation.;Percentage body fat. Timepoint: At baseline, after 12 weeks. Method of measurement: BIA.
|
| Sponsor/Collaborators: |
Vice-chancellor for research, Iran University of Medical Sciences
|
| Gender: |
All
|
| Age: |
20 years60 years
|
| Phases: |
Phase 2
|
| Enrollment: |
105
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.
|
| Start Date: |
14/12/2014
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/2083
|
